Skip to main content
Year archive

Compugen Ltd. — 2021 filings

All 66 regulatory filings released by Compugen Ltd. (CGEN) in 2021, sourced directly from the official regulator.

66 Filings
2021 Period
2021 filings (66)
Filing Released Lang
Compugen Presents Preliminary Translational Data Demonstrating Immune Activation in the Tumor Microenvironment by COM701 at the TIGIT Therapies Digital Summit
Regulatory Filings
2021-12-09 English
Compugen Presents Preliminary Translational Data Demonstrating Immune Activation in the Tumor Microenvironment by COM701 at the TIGIT Therapies Digital Summit
Report Publication Announcement
2021-12-09 English
Documents related to Collaboration Expansion with Bristol Myers Squibb alongside $20 Million Equity Investment
Regulatory Filings
2021-11-12 English
Documents related to Collaboration Expansion with Bristol Myers Squibb alongside $20 Million Equity Investment
Report Publication Announcement
2021-11-12 English
6K-Third Quarter 2021 Results
Regulatory Filings Q3 2021
2021-11-12 English
6K-Third Quarter 2021 Results
Report Publication Announcement
2021-11-12 English
Announces Collaboration Expansion with Bristol Myers Squibb alongside $20 Million Equity Investment
Capital/Financing Update
2021-11-11 English
Announces Collaboration Expansion with Bristol Myers Squibb alongside $20 Million Equity Investment
Report Publication Announcement
2021-11-11 English
Compugen to Present at Upcoming Investor Conferences
Investor Presentation
2021-11-08 English
Compugen to Present at Upcoming Investor Conferences
Report Publication Announcement
2021-11-08 English
o Release Third Quarter 2021 Results on Friday, November 12, 2021
Earnings Release Q3 2021
2021-10-26 English
o Release Third Quarter 2021 Results on Friday, November 12, 2021
Report Publication Announcement
2021-10-26 English
Announces Milestone Payment from AstraZeneca Triggered by First Patient Dosed with TIGIT Bispecific Derived from COM902
Regulatory Filings
2021-10-04 English
Announces Milestone Payment from AstraZeneca Triggered by First Patient Dosed with TIGIT Bispecific Derived from COM902
Report Publication Announcement
2021-10-04 English
Compugen To Present Clinical Data from anti-TIGIT COM902 Monotherapy and Triple Combination Dose Escalation Studies at SITC 2021
AGM Information
2021-10-01 English
Compugen To Present Clinical Data from anti-TIGIT COM902 Monotherapy and Triple Combination Dose Escalation Studies at SITC 2021
Report Publication Announcement
2021-10-01 English
Compugen to Present at the Cantor Global Healthcare Conference
Regulatory Filings
2021-09-14 English
Compugen to Present at the Cantor Global Healthcare Conference
Report Publication Announcement
2021-09-14 English
6K: On September 2, 2021 the “Company held its 2021 Annual General Meeting of Shareholders
Declaration of Voting Results & Voting Rights Announcements
2021-09-03 English
6K: On September 2, 2021 the “Company held its 2021 Annual General Meeting of Shareholders
Report Publication Announcement
2021-09-03 English
Present at the Morgan Stanley 19th Annual Global Healthcare Conference
Regulatory Filings
2021-08-26 English
Present at the Morgan Stanley 19th Annual Global Healthcare Conference
Report Publication Announcement
2021-08-26 English
Compugen Announces Bispecific Antibody Derived from COM902 to Enter Clinical Development
Regulatory Filings
2021-08-19 English
Compugen Announces Bispecific Antibody Derived from COM902 to Enter Clinical Development
Report Publication Announcement
2021-08-19 English
Immediate Report of Meeting to be held on September 2, 2021
AGM Information
2021-07-29 English
Immediate Report of Meeting to be held on September 2, 2021
AGM Information
2021-07-29 English
Compugen Reports Second Quarter 2021 Results
Interim / Quarterly Report H1 2021
2021-07-28 English
Compugen Reports Second Quarter 2021 Results
Report Publication Announcement
2021-07-28 English
First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701 with Opdivo® and Bristol Myers Squibb’s Anti-TIGIT Antibody, BMS-986207
Regulatory Filings
2021-07-19 English
First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701 with Opdivo® and Bristol Myers Squibb’s Anti-TIGIT Antibody, BMS-986207
Report Publication Announcement
2021-07-19 English
Compugen Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patients with Advanced Malignancies
Regulatory Filings
2021-07-15 English
Compugen Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patients with Advanced Malignancies
Report Publication Announcement
2021-07-15 English
to Release Second Quarter 2021 Results and conderence call on Wednesday, July 28, 2021
Report Publication Announcement
2021-07-14 English
to Release Second Quarter 2021 Results and conderence call on Wednesday, July 28, 2021
Report Publication Announcement
2021-07-14 English
Compugen Doses First Patient in COM701/Opdivo® Phase 1b Cohort Expansion Study
Regulatory Filings
2021-06-30 English
Compugen Doses First Patient in COM701/Opdivo® Phase 1b Cohort Expansion Study
Report Publication Announcement
2021-06-30 English
Compugen Presents Research Supporting PVRIG as a Novel and Differentiated Checkpoint in the DNAM-1 Axist
Regulatory Filings
2021-06-29 English
Compugen Presents Research Supporting PVRIG as a Novel and Differentiated Checkpoint in the DNAM-1 Axist
Report Publication Announcement
2021-06-29 English
Compugen Announces Updated Data from Phase 1 Study of COM701, First- in-Class Anti- PVRIG, at the ASCO 2021 Annual Meeting
Regulatory Filings
2021-06-08 English
Compugen Announces Updated Data from Phase 1 Study of COM701, First- in-Class Anti- PVRIG, at the ASCO 2021 Annual Meeting
Report Publication Announcement
2021-06-08 English
Compugen Management to Discuss COM701 Data Presented at ASCO at Event Hosted by Truist Securities
Regulatory Filings
2021-06-01 English
Compugen Management to Discuss COM701 Data Presented at ASCO at Event Hosted by Truist Securities
Report Publication Announcement
2021-06-01 English
6K: Compugen Reports First Quarter 2021 Results
Interim / Quarterly Report Q1 2021
2021-05-13 English
6K: Compugen Reports First Quarter 2021 Results
Report Publication Announcement
2021-05-13 English
Compugen to Participate at SITC’s Targets for Cancer Immunotherapy: A Deep Dive Seminar Series
Regulatory Filings
2021-05-11 English
Compugen to Participate at SITC’s Targets for Cancer Immunotherapy: A Deep Dive Seminar Series
Report Publication Announcement
2021-05-11 English
Expansion of Research Collaboration with Johns Hopkins University for a Novel Myeloid Target Discovered by Compugen
Regulatory Filings
2021-05-10 English
Expansion of Research Collaboration with Johns Hopkins University for a Novel Myeloid Target Discovered by Compugen
Report Publication Announcement
2021-05-10 English
Compugen to Release First Quarter 2021 Results on Thursday, May 13, 2021
Earnings Release Q1 2021
2021-05-03 English
Compugen to Release First Quarter 2021 Results on Thursday, May 13, 2021
Report Publication Announcement
2021-05-03 English
Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the American Society of Clinical Oncology 2021 Annual Meeting
Legal Proceedings Report
2021-04-29 English
Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the American Society of Clinical Oncology 2021 Annual Meeting
Report Publication Announcement
2021-04-29 English
Compugen Publishes Preclinical Data Demonstrating Therapeutic Potential of COM902 in Cancer Immunology, Immunotherapy
Earnings Release Q2 2021
2021-04-27 English
Compugen Publishes Preclinical Data Demonstrating Therapeutic Potential of COM902 in Cancer Immunology, Immunotherapy
Report Publication Announcement
2021-04-27 English
Publishes Review on Biology and Potential Therapeutic Relevance of DNAM-1 axis in Cancer Immunotherapy
Regulatory Filings
2021-03-09 English
Publishes Review on Biology and Potential Therapeutic Relevance of DNAM-1 axis in Cancer Immunotherapy
Report Publication Announcement
2021-03-09 English
to Present at the Oppenheimer 31st Annual Healthcare Conference
Investor Presentation
2021-03-08 English
to Present at the Oppenheimer 31st Annual Healthcare Conference
Report Publication Announcement
2021-03-08 English
Form 20-F for 2020
Annual Report FY 2020
2021-02-26 English
Form 20-F for 2020
Report Publication Announcement FY 2020
2021-02-26 English
Reports Fourth Quarter and Full Year 2020 Results, Announces Data Update from COM701 Phase 1 Clinical Trial
Regulatory Filings
2021-02-25 English
Reports Fourth Quarter and Full Year 2020 Results, Announces Data Update from COM701 Phase 1 Clinical Trial
Report Publication Announcement
2021-02-25 English
Amendment No. 2 to the Master Clinical Trial Collaboration Agreement between the Company and Bristol-Myers Squibb
Regulatory Filings
2021-02-22 English
Amendment No. 2 to the Master Clinical Trial Collaboration Agreement between the Company and Bristol-Myers Squibb
Report Publication Announcement
2021-02-22 English
Compugen to Release Fourth Quarter and Full Year 2020 Results on Thursday, February 25, 2021
Earnings Release FY 2020
2021-02-16 English
Compugen to Release Fourth Quarter and Full Year 2020 Results on Thursday, February 25, 2021
Report Publication Announcement
2021-02-16 English